SJS Investment Consulting’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$44.5K Buy
120
+2
+2% +$706 ﹤0.01% 702
2026
Q2
$42.4K Sell
118
-6
-5% -$1.83K ﹤0.01% 525
2026
Q1
$31.1K Sell
124
-58
-32% -$14.4K ﹤0.01% 541
2025
Q4
$50.1K Buy
182
+46
+34% +$12.6K 0.01% 361
2025
Q3
$35.7K Buy
136
+129
+1,843% +$31.4K ﹤0.01% 418
2025
Q2
$1.53K Sell
7
-3
-30% -$641 ﹤0.01% 660
2025
Q1
$2.24K Sell
10
-2
-17% -$551 ﹤0.01% 676
2024
Q4
$3.93K Buy
12
+5
+71% +$1.57K ﹤0.01% 478
2024
Q3
$2.1K Hold
7
– – ﹤0.01% 764
2024
Q2
$2.31K Sell
7
-1
-13% -$353 ﹤0.01% 652
2024
Q1
$3.17K Hold
8
– – ﹤0.01% 576
2023
Q4
$2.82K Sell
8
-2
-20% -$708 ﹤0.01% 536
2023
Q3
$3.75K Buy
10
+1
+11% +$387 ﹤0.01% 437
2023
Q2
$3.44K Sell
9
-1
-10% -$357 ﹤0.01% 434
2023
Q1
$3.47K Buy
10
+2
+25% +$584 ﹤0.01% 444
2022
Q4
$1.88K Buy
8
+5
+167% +$1.18K ﹤0.01% 657
2022
Q3
$1K Buy
+3
New +$914 ﹤0.01% 953
2022
Q1
$2K Buy
+4
New +$1.57K ﹤0.01% 530

Other funds holding WST

SJS Investment Consulting's WST Position: Q3 2026 in Review

SJS Investment Consulting increased its West Pharmaceutical (WST) stake by 1.7% in Q3 2026, buying an estimated $706 and bringing the position to 120 shares worth $44.5K. The position accounts for ﹤0.01% of the portfolio, ranked #702.

SJS Investment Consulting first reported a position in WST in Q1 2022 and has held it in 18 quarters since. The position peaked at $50.1K in Q4 2025. 813 funds tracked by Wall St. Rank hold WST as of Q3 2026.

  • SJS Investment Consulting held 120 shares of West Pharmaceutical worth $44.5K as of Q3 2026.
  • SJS Investment Consulting bought 2 West Pharmaceutical shares in Q3 2026, an estimated $706.
  • West Pharmaceutical made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #702 holding.
  • SJS Investment Consulting first reported a position in West Pharmaceutical in Q1 2022 and has held it in 18 quarters since.
  • SJS Investment Consulting's West Pharmaceutical position peaked at $50.1K in Q4 2025.
  • 813 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.